Current Report Filing (8-k)
August 03 2022 - 3:33PM
Edgar (US Regulatory)
0001644963
false
0001644963
2022-08-01
2022-08-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
August 1, 2022
Avenue Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) |
001-38114
(Commission File Number)
|
47-4113275
(IRS Employer Identification No.)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section 12(b) of the
Act:
Title of Class |
|
Trading Symbol(s) |
|
Exchange Name |
Common Stock |
|
ATXI |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
On August 1, 2022, the Board of Directors of Avenue
Therapeutics, Inc. (the “Company”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive
Officer, with immediate effect.
Dr. MacLean, 55, previously served as Entrepreneur
in Residence at Fortress Biotech, Inc. (NASDAQ: FBIO), a biopharmaceutical company and a partner company of the Company, from November
2021 through July 2022. She previously served as General Partner and Principal at TVM Capital GmbH, an international life sciences venture
capital firm, from January 2020 through October 2021; as Head of Licensing and Business Development at Imbrium Therapeutics L.P., a clinical-stage
biopharmaceutical company and a subsidiary of Purdue Pharma, L.P. (“Purdue”), from January 2019 through January 2020;
and in various roles at Purdue, a privately held pharmaceutical company, from 2015 to January 2019. Prior to joining Purdue, she served
at Plasma Surgical, Inc., a medical device company, from 2014 to 2015, and Covidien, a medical devices and supplies manufacturer later
acquired by Medtronic plc (NYSE: MDT), from 2010 to 2013. She began her career in the pharmaceutical industry at Merck & Co. (NYSE:
MRK), a pharmaceutical company, where she worked from 2008 to 2010. Dr. MacLean holds an M.D. degree from Columbia University, Vagelos
College of Physicians and Surgeons, an MBA from the University of Colorado – Boulder, and an M.Phil. from the University of Cambridge
in History of Science. She obtained a B.Sc. in Physiology from McGill University.
There are no family relationships between Dr. MacLean
and any directors or executive officers of the company. Additionally, there are no arrangements between Dr. MacLean and any other person
pursuant to which she was appointed as an executive officer. There have been no transactions in which the Company has participated and
in which Dr. MacLean had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation
S-K.
Dr. MacLean does not currently have an employment agreement with the Company but will receive a cash salary in the amount of $332,200 per
year.
With the appointment of Dr. MacLean as the new
Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as
Interim Chief Financial Officer and Chief Operating Officer of the Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AVENUE THERAPEUTICS, INC. |
|
(Registrant) |
|
|
Date: August 3,
2022 |
|
|
|
|
By: |
/s/ David Jin |
|
|
David Jin |
|
|
Interim Principal Financial Officer and Chief Operating Officer |
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Apr 2023 to Apr 2024